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Introduction 
Human papillomavirus (HPV), one of the most 
common sexually transmitted infections (STI) [1], has 
been known to have oncogenic potential for over five 
decades. Beginning with cervical cancer, research is 
now moving on to the implication of HPV infection in 
extragenital sites, such as the oral cavity, the 
oropharynx and the esophagus. The body of evidence 
implicating human papillomavirus as a risk factor in the 
development of esophageal squamous cell carcinoma 
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Abstract  
Human papillomavirus (HPV) is one of the most common sexually transmitted infections. It is strongly linked with the 
development of cervical cancer, and studies are now focusing on HPV infection in extra-genital sites. There is increasing 
evidence implicating HPV as a risk factor in the development of esophageal squamous cell carcinoma. HPV are transmitted 
through micro-abrasions in the epithelial surface, and this occurs for oral and pharyngeal cancers. We hypothesize that oral 
sex (mainly cunnilingus) is the transmission route for the development of HPV-associated esophageal squamous cell 
carcinoma. In addition, we suggest that the use of a HPV vaccine administered to young adolescents in high risk populations 
would greatly reduce the incidence of esophageal cancer and other HPV-associated cancers. 
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(SCC) is growing [2, 3]. We recently conducted a 
meta-analysis which demonstrated an almost three-fold 
increased risk of developing esophageal SCC if there is 
local HPV infection (unpublished data) and HPV 
infection has been found to be an even larger risk factor 
in the development of other cancer groups, for example 
oral SCC (OR: 12.3, 95% CI: 6.3 – 36.6) [1] and 
cervical SCC (OR: 158.2, 95% CI: 113.4 – 220.6) [4]. 
Knowing this, the next step in further understanding the 
pathogenesis of this subset of esophageal cancer is 
looking at the origin of HPV and the method of its 
transmission.  
Human papillomavirus’ are known to be transmitted 
through micro-abrasions in the epithelial surface, 
whereby the HPV virions have access to the basal cell 
layer, and are incorporated into the cells[2]. HPV 16 
and 18 have been found to be ‘high risk’ strains, with an 
increased oncogenic potential when compared to the 
more common strains, 6 and 11, due to differences in 
the expression of certain viral oncogenes (eg. HPV E6 
and E7) [3]. This step is vital to the oncogenic process 
and allows for mutation or interaction with tumour 
suppressor genes[4], in particular binding of HPV 
oncoproteins E6 to p53 and E7 to retinoblastoma 
protein (pRb) [3], and is a cause of cell immortality and 
thus is large part of the carcinogenic process. The 
friction involved in penetrative sexual intercourse is 
thought to be one of the main mechanisms for the 
development of cervical micro-abrasions[3], which 
allow the process to commence and HPV transmission 
to occur. In terms of HPV-associated oropharyngeal 
squamous cell carcinoma (OSCC) research is now 
being directed to the origin of HPV in the oral cavity, 
and the methods of transmission, in order to develop 
preventative measures to decrease the incidence of this 
disease. 
Hypothesis 
Along with its prerequisite role in cervical cancer 
development, HPV is increasingly being implicated in 
the development of upper aerodigestive cancers, such as 
oral, or pharyngeal, and, most recently, esophageal 
SCCs. Genital human papillomavirus is known to be 
transmitted primarily through penetrative sexual 
intercourse which can cause micro-abrasions in the 
epithelial surface and allow for viral transmission. 
Considering the small amount of trauma needed to 
cause these micro-abrasions, it follows that coarse foods, 
hot drinks and repetitive swallowing, for example, 
could have the same effect in the esophagus. Given the 
increased genital HPV prevalence in females and the 
increased HPV-associated esophageal squamous cell 
carcinoma prevalence in males, we postulate that oral 
sexual intercourse, particularly cunnilingus, is a risk 
factor in the genital-esophageal transmission of the 
human papillomavirus and thus plays a part in the 
carcinogenesis of esophageal squamous cell carcinoma. 
We further hypothesise that due to the small percentage 
of people participating in oral sex who utilize barrier 
protection (i.e. condoms), countries with a high risk of 
HPV-associated esophageal squamous cell carcinoma 
should consider the introduction of public health 
immunization programs for people of both genders to 
decrease the risk for individuals and to aid in reducing 
the economic burden of disease. 
Supporting evidence 
Oral-genital transmission of sexually transmitted 
infections is possible and has been implicated as a route 
of transmission for both viral and non-viral infections. 
Viral infections like HIV, Hepatitis C, Herpes Simplex 
Virus as well as bacterial infections like gonorrhea, 
syphilis and Chlamydia thachomatis have all been 
shown to be transmitted via oral-genital sex [5, 6], thus 
opening up the possibility of other viruses, for example 
HPV, being transmitted in a similar manner. 
Current research suggests that oral-genital 
transmission of HPV can occur, and thus oral sex may 
be a factor in the development of oral and or pharyngeal 
squamous cell carcinoma. Chatterjee et al. demonstrated 
oral-genital transmission of HPV in 1998, when they 
found that 41.6% of infants born to cervical HPV 
positive mothers had HPV DNA in the buccal mucosal 
cells [7]. A study of 452 Swedish patients in 2005 then 
showed that high-risk oral HPV infection is 
significantly associated with oral sex [8]. It has also 
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been revealed that the risk of developing HPV 
independently, rises with increases in the number of 
lifetime oral sex partners (p=0.007 for trend) [9]. 
Patients with pharyngeal squamous cell carcinoma have 
been found to be 3.5 times more likely to have engaged 
in oral-genital sex than patients with SCC of other head 
and neck sites [10]. Therefore, it can be seen that oral 
sex is a factor in oral-genital transmission of HPV and 
thus the development of oral and or pharyngeal 
squamous cell carcinoma. Given the similar strains of 
HPV being found present in esophageal SCCs as in 
oropharyngeal SCCs (table 1), we suggest that oral sex 
is a method of transmission in the development of 
esophageal mucosal HPV infection and thus esophageal 
SCC. 
 
 
Table 1 HPV-associated cancers and the most types of HPV detected in each cancer. 
Cancers in which HPV DNA has been detected Most predominant HPV type 
Anogenital Squamous Cell Carcinomas  
Cervix 16, 18 
Vagina 16, 18 
Vulva 16, 18 
Anus 16, 18 
Penis 16, 18 
Upper Aerodigestive Tract Squamous Cell Carcinomas  
Oral cavity 16, 18 
Oropharynx 16, 18 
Larynx 16, 18 
Tonsil 16 
Esophageal  16, 18 
Other  
Squamous cell skin carcinoma Epidermodysplasiaverruciformis-associated HPV 
Periungual squamous cell skin carcinoma  
Squamous cell carcinoma of the eye conjunctiva 16, 18 
 
Oral sex is the most common type of non-coital 
sexual practice, being practiced by over 50% of people 
over the age of 18 [11]. It has been shown that of the 
11% of females and 15% of males aged 15-17years who 
had ever engaged in oral sex reported the use of a 
condom in their most recent oral sex experience. 
However, even for these young people using condoms, 
a meta-analysis conducted in 2002 showed that 
condoms may not prevent genital HPV transmission 
[12], and though more research must be conducted, it 
follows that the use of male condoms may not prevent 
oral-genital HPV transmission either. Conversely, 
studies have shown that the use of female condoms 
confers as much protection from STIs as male condoms, 
and considering the higher prevalence of genital HPV in 
females and thus, the increased risk to males during oral 
sex, this could be an effective method of reducing 
transmission however, more research is needed to 
explore this option. However, for the small number of 
people practicing ‘safe’ oral sex, the use of male 
condoms may not prevent the acquisition of oral or 
esophageal HPV.  
Given the possibility of oral-genital HPV 
transmission, and the possibly ineffective nature of 
condoms as a preventative measure, it is necessary to 
develop other preventative strategies to decrease the 
transmission of HPV and thus decrease the incidence of 
HPV-associated esophageal squamous cell carcinoma. 
In 2006, a quadrivalent vaccine (Gardasil) targeting 
HPV 6, 11, 16 and 18, was introduced in several 
countries and since then a bivalent vaccine (Cervarix), 
targeting HPV 16 and 18, has also been introduced. 
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Together, these vaccinations have demonstrated >90% 
efficacy against persistent HPV 16 and 18 infection 
[13].  
 
Economic burden of primary 
prevention 
 
Given that China is one of the highest risk countries for 
HPV-associated esophageal squamous cell carcinoma 
(unpublished data), we assessed the benefit of 
implementing a vaccination program in Chinese people 
aged 10-14 years.  
The U.S. Census Bureau reported that in 2012 the 
number of people in China aged 10-14, being the 
target-group for HPV vaccination [14], is 80,407,556 
[15]. Using an estimated cost of vaccinating one person 
in a school-based program of US$300 [14], we 
calculated that the cost of vaccinating the entire target 
group would be just over US$24 billion.  
We also found the aged standardized risk of esophageal 
cancer in China is 16.7/100,000 in 2012 [16], and given 
that the current population in China is estimated at 
1,343,240,000 [15], it can be extrapolated that the 
yearly incidence of esophageal cancer in China would 
be approximately 224,321. Given the prevalence of 
HPV DNA in esophageal SCC in China is estimated to 
be 46.9% [19], we calculated that the yearly incidence 
of HPV-associated esophageal cancer in China would 
be approximately 105,206. Using methodology from 
Sanders et al. the vaccine efficacy against high-risk 
HPV type was estimated at 75% [14], though actually it 
has been found to be much higher [17]. However, using 
this 75% estimate, we found that an estimated 78,905 
cases of esophageal cancer would be prevented should 
the vaccine be implemented.  
Given that the 5-year survival rate of esophageal cancer 
patients is 12.5% [18], based on data published by 
Yabroff et al. in 2008, we estimated that the cost of 
treating each esophageal cancer patient for five years is 
US$117,325 [18]. Therefore, given the incidence, the 
cost of treating esophageal cancer patients in China is 
estimated to be over US$26.3 billion. Should the 
vaccine be implemented and over 78,000 of these cases 
be prevented, the cost of treating esophageal cancer 
patients would be reduced to just over US$17 billion. 
Consequently, it can be extrapolated that while the cost 
of vaccinating all Chinese people aged 10-14 is 
approximately US$14.8 billion more than that saved by 
its implementation, over 78,000 cases of esophageal 
cancer would be prevented. While the cost difference 
appears to be large, this is not the only cancer type the 
vaccine would target – implementation of the vaccine 
has been shown to prevent up to 98% of cervical 
intraepithelial neoplasia (CIN) grade 2 or worse [19]. 
Given that current estimates indicate that 75434 
Chinese women are diagnosed with cervical cancer 
each year [20], implementation of the vaccine would 
potentially prevent 73925 of these. Using the same 
method as for esophageal cancer, we calculated the 
amount saved in the treatment of cervical cancer should 
be vaccine be implemented at over US$4.2 billion [18].  
Therefore the total amount saved on the treatment of 
esophageal and cervical cancer patients should the 
vaccine be implemented would be over US$19 billion, 
and over 150,000 patients would be prevented from 
developing cancer. In addition, the vaccine, given the 
association between HPV and other cancer types (table 
1), has the potential effect the lives of many more 
people who may have developed other HPV-associated 
cancers.  
Limitations 
The evaluation of cost-effectiveness is limited by the 
assumption that in most cases, HPV is a direct cause of 
esophageal carcinoma. It is a basic demonstration of the 
financial implications of implementing the vaccine, and 
would have different results given the population and 
incidence HPV and esophageal carcinoma in the 
country being analysed.  
 
 
Conclusion 
 
In 2010, it was reported that esophageal cancer is one of 
only three types of cancer (the others being liver and 
intrahepatic bile duct and melanoma of the skin), which, 
between 1990 and 2006, had an overall rise in the 
mortality rate among males, increasing by 9.7% [21]. 
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This increase demonstrates the need for further research 
into the causes of esophageal cancer and thus 
prevention, screening, and treatment options. Should 
more research be conducted, we believe that it would 
prove that oral sex, particularly cunnilingus, is a factor 
in the implantation of HPV DNA into the esophageal 
mucosa through micro-abrasions in the epithelial 
surface. This knowledge could facilitate the 
development of an advocacy program with the aim of 
changing the perception of oral sex as a ‘safe’ form of 
sexual intercourse, and preventing the transmission of 
many STIs.  
The introduction of vaccination programs as a primary 
preventative measure in high-risk areas for the 
development of HPV-associated esophageal squamous 
cell carcinomas, like Asia, and in particular China, 
could have a huge impact on the number of incident 
cases of this cancer diagnosed each year. However, the 
vaccine would also target other HPV-associated cancer 
groups, and in effect have a much greater influence on 
incidence rates of over 10 different types of cancer. 
Should the program be implemented in a country like 
China, for example, the implementation of a 
vaccination program would impact on the lives of over 
150,000 Chinese people – and considering this is only 
taking into account esophageal and cervical cancer 
patients, this is a conservative estimate and the number 
would, in fact, be much larger.  
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